Get the equipment you need without draining your capital. NFS Capital delivers flexible equipment financing for biotech and life sciences companies outside traditional lending criteria. Learn more here.
iTeos Therapeutics is throwing in the towel. Two weeks after axing its GSK-partnered TIGIT candidate, the biotech has decided to wind down operations, sell its assets and return as much of its $600 million-plus cash pile to investors as possible.
Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion acquisition of Chinook, including a former director of the biotech’s board.
Bridging the gap between research and the clinic—GenScript’s GMP-like mRNA accelerates your path to IND with phase-appropriate quality for next-gen therapeutics.
Biotech stories don’t stop at the science. Keep yours in front of R&D leaders and investors with a content strategy built for high engagement. Our multi-touch emails and syndication tools meet your audience where they already are. Let's Talk
Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor. The update provides a closer look at the hand Merck is holding as it gears up to fight Daiichi Sankyo and Ono Pharmaceutical for the tenosynovial giant cell tumor market.
An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of CRISPR on human embryos.
An independent data monitoring committee assessing a phase 3 trial for InflaRx's vilobelimab in pyoderma gangrenosum has urged the German drugmaker to stop the study early for futility. Given the trial’s outcome, InflaRx said it plans to stop development of vilobelimab in the rare inflammatory skin disorder.
The CDC's recommended immunization schedule no longer includes COVID vaccines for healthy children and pregnant women, HHS secretary Robert F. Kennedy Jr. announced on Tuesday.
This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold.
Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now.
Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process.
We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned.
Presented by Blue Matter, strategic consultants in the life sciences
